# Stoke Therapeutics FDA Win Boosts Market Hopes

> FDA approval for zorevunersen's cognition endpoint could reshape Dravet syndrome treatment outlook.
- Title: Stoke Therapeutics FDA Win Boosts Market Hopes · Seekingalpha
- Summary: FDA approval for zorevunersen's cognition endpoint could reshape Dravet syndrome treatment outlook. Stoke Therapeutics' FDA acceptance of cognition/behavior…
- Keywords: stoke therapeutics, zorevunersen, dravet syndrome, fda, cognition endpoint, market misread, money, business, Stoke, Therapeutics, Win, Boosts
- Source: Seekingalpha — https://seekingalpha.com/article/4955308-stoke-therapeutics-the-market-misread-a-key-fda-win
- Author: Equity Eagle
- Published: 2026-10-19T20:34:29+00:00
- Read time: 1 min
- Topics: stoke therapeutics, zorevunersen, dravet syndrome, fda, cognition endpoint, market misread, money, business
## FDA Cognition Endpoint Approval
The FDA accepted a cognition/behavior endpoint for zorevunersen, potentially the first disease-modifying Dravet syndrome therapy.

> The FDA’s acceptance of a cognition/behavior endpoint for EMPEROR reduces regulatory risk and differentiates zorevunersen from symptomatic competitors
## Cash Runway and Share Sale
Stoke Therapeutics has $420M cash and completed a $65.7M share sale at a premium to market, extending cash runway to early 2028.
## 2027 Readout Probability
Current valuation implies only a 30, 40% probability of EMPEROR success, offering asymmetric risk/reward ahead of the 2027 catalyst.
## Key takeaway

Stoke Therapeutics' FDA acceptance of cognition/behavior endpoint for zorevunersen reduces regulatory risk for Dravet syndrome therapy.